Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Abstract Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is < 40% due to rel...
Main Authors: | Xiang Zhang, Jiejing Qian, Huafeng Wang, Yungui Wang, Yi Zhang, Pengxu Qian, Yinjun Lou, Jie Jin, Honghu Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-021-00288-7 |
Similar Items
-
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01) -
225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
by: Ravendra Garg, et al.
Published: (2021-02-01) -
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
by: Hyunsoo Cho, et al.
Published: (2021-04-01) -
Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01) -
The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
by: Aleksina Shatilova, et al.
Published: (2021-05-01)